Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Libby, A. M. Articles by Valuck, R. J. Search for Related Content PubMed Citation Articles by Libby, A. M. Articles by Valuck, R. J. Health Policy and Legislation Depression Antidepressants Related Article

Decline in Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality With SSRIs

OBJECTIVE: In October 2003, the U.S. Food and Drug Administration (FDA) issued a public health advisory about the risk of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depression. This study used data from a large national pediatric cohort to examine patterns of diagnosis of depression, prescription of antidepressants, prescription of pharmacological alternatives to antidepressants, and use of psychosocial care before and after the FDA advisory was issued. METHOD: A large pediatric cohort with newly diagnosed episodes of depression was created from a national integrated claims database of managed care plans from October 1998 to September 2005 (N=65,349). Time-series models were used to compare diagnosing and prescribing trends during the 2 years after the FDA advisory and the expected trends based on data from the 5-year period preceding the advisory. RESULTS: From 1999 to 2004, pediatric diagnoses of depression increased from 3 to 5 per 1,000. After the FDA advisory was issued, the national rate decreased to 1999 levels, a significant deviation from the historical trend. Pediatricians and nonpediatrician primary care physicians accounted for the largest reductions in new diagnoses. Among patients with depression, the proportion receiving no antidepressant increased to three times the rate predicted by the preadvisory trend, and SSRI prescription fills were 58% lower than predicted by the trend. There was no evidence of a significant increase in use of treatment alternatives (psychotherapy, atypical antipsychotics, and anxiolytics). CONCLUSIONS: The FDA advisory was associated with significant reductions in aggregate rates of diagnosis and treatment of pediatric depression.

Related Article:

In This Issue
Am J Psychiatry 2007 164: A38. [Full Text] [PDF]

This article has been cited by other articles:

				J. A. Bridge, J. B. Greenhouse, A. H. Weldon, J. V. Campo, and K. J. Kelleher Suicide Trends Among Youths Aged 10 to 19 Years in the United States, 1996-2005 JAMA, September 3, 2008; 300(9): 1025 - 1026. [Full Text] [PDF]

				E. M. Tsapakis*, F. Soldani*, L. Tondo, and R. J. Baldessarini Efficacy of antidepressants in juvenile depression: meta-analysis The British Journal of Psychiatry, July 1, 2008; 193(1): 10 - 17. [Abstract] [Full Text] [PDF]

				I. Anghelescu and F. Regen SSRI Tapering and Suicidal Ideation in the TORDIA Study for Treatment of Depressed Adolescents JAMA, June 18, 2008; 299(23): 2745 - 2746. [Full Text] [PDF]

				L. Y. Katz MD, A. L. Kozyrskyj PhD, H. J. Prior MSc, M. W. Enns MD, B. J. Cox PhD, and J. Sareen MD Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults Can. Med. Assoc. J., April 8, 2008; 178(8): 1005 - 1011. [Abstract] [Full Text] [PDF]

				B. W Wheeler, D. Gunnell, C. Metcalfe, P. Stephens, and R. M Martin The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study BMJ, March 8, 2008; 336(7643): 542 - 545. [Abstract] [Full Text] [PDF]

				B. Vitiello and J. L. Pearson A Depressed Adolescent at High Risk of Suicidal Behavior Am J Psychiatry, March 1, 2008; 165(3): 323 - 328. [Full Text] [PDF]

				D. Brent, G. Emslie, G. Clarke, K. D. Wagner, J. R. Asarnow, M. Keller, B. Vitiello, L. Ritz, S. Iyengar, K. Abebe, et al. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial JAMA, February 27, 2008; 299(8): 901 - 913. [Abstract] [Full Text] [PDF]

				P. Clayton and T. Auster Strategies for the Prevention and Treatment of Suicidal Behavior Focus, January 1, 2008; 6(1): 15 - 21. [Abstract] [Full Text] [PDF]

				E. H. Morrato, A. M. Libby, H. D. Orton, F. V. deGruy III, D. A. Brent, R. Allen, and R. J. Valuck Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality With SSRIs Am J Psychiatry, January 1, 2008; 165(1): 42 - 50. [Abstract] [Full Text] [PDF]

				A. James Pharmacotherapy and child psychiatry: is there a way forward?: INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY Advan. Psychiatr. Treat., January 1, 2008; 14(1): 10 - 16. [Abstract] [Full Text] [PDF]

				T. WOHLFARTH, F. BOER, and W. van den BRINK Withdrawal of Attention Rather Than Pharmacological Treatment Affects Suicide Rates in Depressed Children and Adolescents Am J Psychiatry, December 1, 2007; 164(12): 1908 - 1908. [Full Text] [PDF]

				R. D. Gibbons, C. H. Brown, K. Hur, S. M. Marcus, D. K. Bhaumik, J. A. Erkens, R. M.C. Herings, and J. J. Mann Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents Am J Psychiatry, September 1, 2007; 164(9): 1356 - 1363. [Abstract] [Full Text] [PDF]

				J. A. Bridge, B. Birmaher, and D. A. Brent Benefits and Harms of Pediatric Antidepressant Medications Reply JAMA, August 8, 2007; 298(6): 627 - 627. [Full Text] [PDF]

				R. J. Valuck, A. M. Libby, H. D. Orton, E. H. Morrato, R. Allen, and R. J. Baldessarini Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs Am J Psychiatry, August 1, 2007; 164(8): 1198 - 1205. [Abstract] [Full Text] [PDF]

				D. F. Klein and C. P. O'Brien Improving Detection of Adverse Effects of Marketed Drugs JAMA, July 18, 2007; 298(3): 333 - 334. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us